Major hepatectomy with combined vascular resection for perihilar cholangiocarcinoma

被引:20
作者
Sugiura, T. [1 ]
Uesaka, K. [1 ]
Okamura, Y. [1 ]
Ito, T. [1 ]
Yamamoto, Y. [1 ]
Ashida, R. [1 ]
Ohgi, K. [1 ]
Otsuka, S. [1 ]
Nakagawa, M. [2 ]
Aramaki, T. [3 ]
Asakura, K. [3 ]
机构
[1] Shizuoka Canc Ctr, Div Hepatobiliarypancreat Surg, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Div Plast & Reconstruct Surg, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka, Japan
来源
BJS OPEN | 2021年 / 5卷 / 04期
关键词
PORTAL-VEIN RESECTION; LEFT HEPATIC TRISECTIONECTOMY; HILAR CHOLANGIOCARCINOMA; CLINICAL-SIGNIFICANCE; COMPUTED-TOMOGRAPHY; ARTERY RESECTION; RECONSTRUCTION; MORTALITY; OUTCOMES; HEMIHEPATECTOMY;
D O I
10.1093/bjsopen/zrab064
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Hepatectomy with vascular resection (VR) for perihilar cholangiocarcinoma (PHCC) is a challenging procedure. However, only a few reports on this procedure have been published and its clinical significance has not been fully evaluated. Methods: Patients undergoing surgical resection for PHCC from 2002-2017 were studied. The surgical outcomes of VR and non-VR groups were compared. Results: Some 238 patients were included. VR was performed in 85 patients. The resected vessels were hepatic artery alone (31 patients), portal vein alone (37 patients) or both (17 patients). The morbidity rates were almost the same in the VR (49.4 per cent) and non-VR (43.8 per cent) groups (P = 0.404). The mortality rates of VR (3.5 per cent) and non-VR (3.3 per cent) were also comparable (P>0.999). The median survival time (MST) was 45 months in the non-VR group and 36 months in VR group (P = 0.124). Among patients in whom tumour involvement was suspected on preoperative imaging and whose carbohydrate antigen 19-9 (CA19-9) value was 37 U/ml or less, MST in the VR group was significantly longer than that in the non-VR group (50 versus 34 months, P = 0.017). In contrast, when the CA19-9 value was greater than 37 U/ml, MST of the VR and non-VR groups was comparable (28 versus 29 months, P = 0.520). Conclusion: Hepatectomy with VR for PHCC can be performed in a highly specialized hepatobiliary centre with equivalent short- and long-term outcomes to hepatectomy without VR.
引用
收藏
页数:9
相关论文
共 50 条
[1]   Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma [J].
Abbas, Saleh ;
Sandroussi, Charbel .
HPB, 2013, 15 (07) :492-503
[2]   Multi-detector computed tomography angiography of the hepatic artery in liver transplant recipients [J].
Boraschi, P ;
Donati, F ;
Cossu, MC ;
Gigoni, R ;
Vignali, C ;
Filipponi, F ;
Bartolozzi, C ;
Falaschi, F .
ACTA RADIOLOGICA, 2005, 46 (05) :455-461
[3]   Combined portal vein resection in the treatment of hilar cholangiocarcinoma: A systematic review and meta-analysis [J].
Chen, W. ;
Ke, K. ;
Chen, Y. L. .
EJSO, 2014, 40 (05) :489-495
[4]   Preoperative Serum CA 19-9 Level as a Predictive Factor for Recurrence after Curative Resection in Biliary Tract Cancer [J].
Chung, Moon Jae ;
Lee, Kyong Joo ;
Bang, Seungmin ;
Park, Seung Woo ;
Kim, Kyung Sik ;
Lee, Woo Jung ;
Song, Si Young ;
Chung, Jae Bock ;
Park, Jeong Youp .
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (06) :1651-1656
[5]  
Coelho Rosa, 2017, GE Port J Gastroenterol, V24, P114, DOI 10.1159/000452691
[6]   The impact of portal vein resection on outcomes for hilar cholangiocarcinoma [J].
de Jong, Mechteld C. ;
Marques, Hugo ;
Clary, Bryan M. ;
Bauer, Todd W. ;
Marsh, J. Wallis ;
Ribero, Dario ;
Majno, Pietro ;
Hatzaras, Ioannis ;
Walters, Dustin M. ;
Barbas, Andrew S. ;
Mega, Raquel ;
Schulick, Richard D. ;
Choti, Michael A. ;
Geller, David A. ;
Barroso, Eduardo ;
Mentha, Gilles ;
Capussotti, Lorenzo ;
Pawlik, Timothy M. .
CANCER, 2012, 118 (19) :4737-4747
[7]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[8]   Hepatectomy with portal vein resection for hilar cholangiocarcinoma - Audit of 52 consecutive cases [J].
Ebata, T ;
Nagino, M ;
Kamiya, J ;
Uesaka, K ;
Nagasaka, T ;
Nimura, Y .
ANNALS OF SURGERY, 2003, 238 (05) :720-727
[9]   Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer [J].
Ebata, T. ;
Hirano, S. ;
Konishi, M. ;
Uesaka, K. ;
Tsuchiya, Y. ;
Ohtsuka, M. ;
Kaneoka, Y. ;
Yamamoto, M. ;
Ambo, Y. ;
Shimizu, Y. ;
Ozawa, F. ;
Fukutomi, A. ;
Ando, M. ;
Nimura, Y. ;
Nagino, M. .
BRITISH JOURNAL OF SURGERY, 2018, 105 (03) :192-202
[10]   Left hepatic trisectionectomy for advanced perihilar cholangiocarcinoma [J].
Esaki, M. ;
Shimada, K. ;
Nara, S. ;
Kishi, Y. ;
Sakamoto, Y. ;
Kosuge, T. ;
Sano, T. .
BRITISH JOURNAL OF SURGERY, 2013, 100 (06) :801-807